February - 2025

top of page

Subscribe to our newsletter

News

Categories

Sign up

Featured Posts

How Israeli technology saved 78-year-old Leah from skin cancer

How Israeli technology saved 78-year-old Leah from skin cancer

Alpha-emitting Radiation Therapy Could Create a Paradigm Shift in Cancer Treatment

Alpha-emitting Radiation Therapy Could Create a Paradigm Shift in Cancer Treatment

Alpha DaRT treatment proves a success in first-in-human trial

Alpha DaRT treatment proves a success in first-in-human trial

Israel's alpha radiation treatment shows tumor shrinkage in 100% of cases

Israel's alpha radiation treatment shows tumor shrinkage in 100% of cases

Alpha Tau Announces the Publication of Exceptional Clinical Data from Alpha DaRT, its Novel Alpha Ra

Alpha Tau Announces the Publication of Exceptional Clinical Data from Alpha DaRT, its Novel Alpha Ra

Israeli MedTech Start-up, Alpha Tau Medical, Raises $29 Million in Private Financing to Cure Cancer

Israeli MedTech Start-up, Alpha Tau Medical, Raises $29 Million in Private Financing to Cure Cancer

Alpha Tau’s High-Precision Cancer Radiotherapy Receives Radioactive-Safety Approval in the United St

Alpha Tau’s High-Precision Cancer Radiotherapy Receives Radioactive-Safety Approval in the United St

First Alpha Tau Medical Summit Gathers Over 200 Oncologists and Physicians From all Around the World

First Alpha Tau Medical Summit Gathers Over 200 Oncologists and Physicians From all Around the World

Archive

Follow Us

Alpha Tau to Participate in March Investor Conferences

Alpha Tau to Participate in March Investor Conferences

JERUSALEM, February 27, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...

Feb 27

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Feb 24

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Coh

Feb 3

bottom of page